Yipinhong announced that the cumulative deviation of the closing price increase of the company's stock from May 19 to 21 for three consecutive trading days exceeded 30%, which is an abnormal fluctuation in stock trading. The company's innovative drug AR882, which is under research and development, still needs to conduct Phase III clinical studies at home and abroad and be approved by the drug review department before it can be marketed. Whether it can pass the final approval of the regulatory authorities, be approved for listing and the time of listing is uncertain. AR882 has not yet been marketed and sold, and has not generated sales revenue, which will not have a significant impact on the company's recent performance.